Company intelligence / Profile preview

Avenna

Ownership: Private
Development stage: Commercial

Overview

Avenna has developed blood tests that use glycomics patterns to measure general and disease-specific inflammation before tissue or organ damage occurs. Their technology enables earlier diagnosis, prognosis, and personalized treatment planning in chronic inflammatory diseases. They are currently validating patient-centric microsampling methods in collaboration with Trajan Scientific & Medical. No published interventional clinical trial results; focus on test development/validation.

Therapeutic areas: OtherImmunology
Modalities: Glycomic biomarkersdiagnostic assays (focus on blood-based glycomics for inflammatory diseases)
Industry: Protein Biomarker Diagnostics

Partnerships

Trajan Scientific & Medical / Neoteryx – partnership to validate patient-centric microsampling devices using VAMS® technology for remote sample collection in their studies.

Beyond the preview

Go deeper on Avenna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avenna.

Explore the full profile